|
NPPA fixes retail price of 36 formulations including anti-diabetic drugs
|
|
Gireesh Babu, New Delhi
January 12 , 2023
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 36 formulations under the Drugs (Prices Control) Order, 2013, based on the decision taken at the Authority meeting held recently.
The formulations for which the prices have been fixed include various strengths of anti-diabetic drug sitagliptin phosphate and metformin hydrochloride tablets manufactured by Pure and Cure Healthcare Pvt Ltd and marketed by Natco Pharma.
The NPPA has also fixed retail price of anti-diabetic fixed dose combinations (FDCs) of dapagliflozin, sitagliptin and metformin hydrochloride as extended release tablets manufactured by Exemed Pharmaceuticals for various companies for marketing, including, USV Pvt Ltd, Emcure Pharmaceuticals, Zydus Healthcare, Alembic Pharmaceuticals, Glenmark Pharmaceuticals, Intas Pharmaceuticals, Eris Life Sciences Ltd, Cipla Ltd, Micro Labs Ltd, Torrent Pharmaceuticals Ltd, Abbott Healthcare Pvt Ltd, Lupin Ltd, and Cadila Pharmaceuticals.
Besides, retail price has been fixed for metronidazole, furazolidone and dicyclomine hydrochloride tablets manufactured by Dallas Drugs Pvt Ltd and marketed by Micro Labs Pvt Ltd, atorvastatin and bempedoic acid tablet manufactured by Exemed Pharmaceuticals and marketed by Torrent Pharmaceuticals, Telmisartan and bisoprolol tablets manufactured and marketed by Micro Labs, lidocaine patch 5 per cent manufactured and marketed by Hetero Healthcare Ltd, levetiracetam infusion manufactured by Akums Drugs and Pharmaceuticals and marketed by Cipla Ltd, among others.
The manufacturer may add Goods and Services Tax (GST), only if they have paid actually or it is payable to the Government on the retail price mentioned in the Order, said the Authority.
The prices were fixed by the NPPA in an Authority meeting held on December 30, 2022. It has also approved the revised ceiling price of 97 scheduled formulations in the meeting, including sulfasalazine tablet 500 mg, digoxin tablet 0.25 mg, ethambutol tablet 600 mg, Phenytoin tablet 300 mg, atazanavir 300 mg + ritonavir 100 mg tablet, ceftriaxone powder for injection in 250 mg, 500 mg, 1000 mg and 2000 mg strengths, cefotaxime powder for injection 250 mg, 500 mg, and 1000 mg, piperacillin and tazobactam combinations, ampicillin powder for injection 500 mg, metoprolol tablet 25 mg and 50 mg, among others.
The price regulator, through two orders on January 9, 2023, fixed the revised ceiling prices, as per the Schedule I of the DPCO, 2013, which was recently amended with the National List of Essential Medicines (NLEM), 2022.
The Authority has also issued a corrigendum revising the ceiling price for 31 out of the 117 formulations it fixed in December, based on the data submitted by the companies.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|